RxDoctor Payments DataLook up a doctor →

Chad Cherington, MD

Hematology & Oncology · Mesa, AZNPI 1285952390

Payments from drug & device makers

$781,475in general payments, 2019–2025

Across 1,178 payments — averaging $663.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$609K
  • Pfizer$138K
  • Bayer$3K
  • Global Blood Therapeutics, Inc.$3K
  • Kyowa Kirin, Inc.$3K
  • Springworks Therapeutics, Inc.$2K
  • plus $23K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)70$609,313
Pfizer89$138,405
Bayer26$3,150
Global Blood Therapeutics, Inc.9$2,651
Kyowa Kirin, Inc.8$2,536
Springworks Therapeutics, Inc.11$2,089
Servier Pharmaceuticals LLC6$1,861
AVEO Pharmaceuticals, Inc.11$1,767
Astellas Pharma Global Development2$1,427
Johnson & Johnson(2 entities)77$1,384
Novartis87$1,349
Exelixis Inc.11$1,181
Bristol Myers Squibb68$1,037
E.r. Squibb & Sons, L.L.C.86$971
Genentech USA, Inc.42$835
Astellas Pharma US Inc31$778
Merck41$731
Sanofi39$667
Amgen38$660
Seagen Inc.39$612
Daiichi Sankyo Inc.28$563
Regeneron Healthcare Solutions, Inc.19$535
AbbVie29$525
Pharmacyclics LLC, An Abbvie Company34$524
Gilead(2 entities)27$493
Eisai Inc.20$399
Takeda Pharmaceuticals U.S.A., Inc.16$388
Rigel Pharmaceuticals, Inc.13$341
GSK16$336
Incyte Corporation17$308
Array Biopharma Inc19$266
Lilly USA, LLC9$238
Novocure GmbH1$200
Sirtex Medical Inc1$180
Ipsen Biopharmaceuticals, Inc11$177
Myovant Sciences Inc.10$164
EMD Serono, Inc.9$159
Jazz Pharmaceuticals Inc.7$156
Dova Pharmaceuticals9$150
Puma Biotechnology, Inc.7$135
Blueprint Medicines Corporation7$108
Karyopharm Therapeutics Inc.4$105
Taiho Oncology, Inc.5$93
Intuitive Surgical1$93
Penumbra, Inc.1$91
Sobi, Inc4$89
Tersera Therapeutics LLC4$85
Janssen Scientific Affairs, LLC2$84
Epizyme, Inc.5$83
Sun Pharmaceutical Industries Inc.4$79
Mirati Therapeutics, Inc.4$74
Clovis Oncology, Inc.4$68
Organon4$65
CTI Biopharma Corp.3$62
Boehringer Ingelheim3$57
Medexus Pharma, Inc.1$57
Beigene USA, Inc.3$50
Iovance Biotherapeutics, Inc.2$48
Adaptive Biotechnologies Corporation2$40
Aurobindo Pharma USA, Inc.3$39

How this compares

$781,475 in reported general payments places this provider in the 80th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Medicare billing

Part B allowed, 2024
$1,771,048
Medicare patients
480
Services billed
75,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Mesa

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →